Telemus Capital, LLC Biogen Inc. Transaction History

Telemus Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 27, 2021	SELL	$282.99 - $369.05 $641,538 - $836,636	-2,267 Closed	0 $0
Q2 2021 Aug 09, 2021	SELL	$259.0 - $414.71 $62,419 - $99,945	-241 Reduced 9.61%	2,267 $785,000
Q1 2021 Apr 20, 2021	BUY	$242.95 - $284.63 $54,177 - $63,472	223 Added 9.76%	2,508 $697,000
Q4 2020 Jan 28, 2021	BUY	$236.26 - $355.63 $165,618 - $249,296	701 Added 44.26%	2,285 $560,000
Q3 2020 Nov 02, 2020	BUY	$264.77 - $305.71 $419,395 - $484,244	1,584 New	1,584 $444,000
Q2 2019 Aug 09, 2019	SELL	$219.29 - $241.72 $213,588 - $235,435	-974 Closed	0 $0
Q1 2019 May 02, 2019	BUY	$216.71 - $338.96 $211,075 - $330,147	974 New	974 $230,000
Q4 2018 Feb 06, 2019	SELL	$278.5 - $352.75 $189,380 - $239,870	-680 Closed	0 $0
Q3 2018 Oct 23, 2018	BUY	$293.51 - $383.83 $199,586 - $261,004	680 New	680 $240,000
Q1 2018 Apr 27, 2018	SELL	$260.13 - $367.91 $59,829 - $84,619	-230 Closed	0 $0
Q4 2017 Feb 02, 2018	BUY	$307.64 - $344.58 $70,757 - $79,253	230	230 $73,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Telemus Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Telemus Capital, LLC with notifications on news.